Clinical Trial Update: Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating a quadruple combination of Iparomlimab, Tuvonralimab, Apatinib, and Irinotecan hydrochloride for advanced Alpha-fetoprotein-producin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-fetoprotein-producing Gastric Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Apatinib (apatinib)
• IRINOTECAN HYDROCHLORIDE (irinotecan hydrochloride)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4 | Phase 2 | Status: RECRUITING